Clinical OMICS

SEP-OCT 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1023557

Contents of this Issue

Navigation

Page 13 of 51

12 Clinical OMICs September/October 2018 www.clinicalomics.com I n the absence of a cure, the number of people who suffer from neurodegenerative diseases in the future will be staggering. Because these diseases primarily strike older people, and our aging population is increasing, it is estimated that more than 12 million Americans will be afflicted by neurodegeneration 30 years from now (roughly 1 in 5 Americans will be over the age of 65 by the year 2030). Some progress has been made in developing treatments for neurodegenerative dis- eases, but far too slowly. One of the reasons for that is the lack of a full understanding of the basic biology of the diseases, something that researchers are trying to change. Some of the most exciting research going on in the Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) fields takes an "omics" approach to better understand the biology behind these diseases, which will undoubtedly open doors to new therapeutics. Seeking Answers in PD-Associated Genes A team of researchers in the human genetics group at Genentech, led by Rob Graham, Ph.D., a senior scientist who has worked in the department for 11 years, works to identify new therapeutic targets and pathways associated with disease risk and progression. Most recently, that work centered on identifying novel genes involved in PD. "We're still trying to understand the basic biology of PD," Graham said. "When we do that, we can more intelligently think about how to target the disease." He added that despite significant effort and some progress in PD research, "things have moved more slowly than we would all like." More than 30 years ago, Robert Nussbaum's, M.D., group at the National Institutes of Health (NIH) discovered that mutations in SNCA (which encodes alpha-synuclein) were common in several families with a high prevalence of Parkinson's. The paper, "Mutation in the alpha-synuclein gene identified in families with Parkin- son's disease" was published in Science in 1997. Since Julianna LeMieux, Ph.D. Senior Editor Armed with New Tools and Lower Cost Sequencing, Researchers Take an Omics Approach to Neuro Diseases New Tack Neurodegenerative Disease Research for John Lund / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - SEP-OCT 2018